Stockreport

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

Theriva Biologics, Inc.  (TOVX) 
PDF - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in mult [Read more]